Evidence map›Paper›PMID 32550752›Full record

ReviewWorld journal of gastroenterology2020

Vaccine therapy for dysbiosis-related diseases.

Kosuke Fujimoto, Satoshi Uematsu

Open access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kosuke FujimotoDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Satoshi UematsuDepartment of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases, such as obesity, diabetes, rheumatoid arthritis, and inflammatory bowel diseases represented by Crohn's disease and ulcerative colitis. Dysregulated gut microbiome contributes to the pathogenesis of such disorders; however, there are few effective treatments for controlling only disease-mediating bacteria. Here, we review current knowledge about the intestinal microbiome in health and disease, and discuss a regulatory strategy using a parenteral vaccine with emulsified curdlan and CpG oligodeoxynucleotides, which we have recently developed. Unlike other conventional injectable immunizations, our vaccine contributes to the induction of antigen-specific systemic and mucosal immunity. This vaccine strategy can prevent infectious diseases such as

Indexed as

Administration, MucosalArthritis, RheumatoidBacterial Vaccinesbeta-GlucansDiabetes Mellitus, Type 2DysbiosisGastrointestinal MicrobiomeHumansImmunity, MucosalImmunization ScheduleImmunization, SecondaryImmunoglobulin AInflammatory Bowel DiseasesInjections, IntramuscularIntestinal MucosaObesityBacterial Vaccinesbeta-GlucanscurdlanGpG-oligonucleotideImmunoglobulin AOligodeoxyribonucleotidesPolysaccharides, BacterialVaccines, SyntheticDysbiosisIgAMicrobiomeMucosal immunityPathobiontVaccine

Identifiers

PMID32550752
PMCPMC7284185
OpenAlexW3033062113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.